ArticleOncoimmunology2016
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
Ming Cheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this papercites it